Vanguard MSCI Index International Shares Etf

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Betashares Australian Resources Sector Etf

QRE

QRE.AX was created on 2010-12-10 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 162.36m in AUM and 43 holdings. QRE.AX aims to track the performance an index (before fees and expenses) comprising the largest ASX-listed companies in the resources sector, including BHP, Rio Tinto, Woodside Petroleum and more.

iShares S&P 500 Etf

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

Paradigm Biopharmaceuticals Limited.

PAR

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is focused on developing and commercializing pentosan polysulfate sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, infection, or genetic predisposition. PPS is a semi-synthetic drug manufactured from European beech xylans that are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). Its multiple actions of PPS are mediated by targeting both NF-kB-dependent and NF-kB-independent pathways. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), mucopolysaccharidosis (MPS), chronic heart failure (CHF) and alpha-viral arthritis (Ross River Virus and Chikungunya).

Sayona Mining Limited

SYA

Sayona Mining Ltd. engages in sourcing and developing raw materials required for constructing lithium-ion batteries. In Quebec, the Company’s assets comprise North American Lithium (NAL) together with the Authier Lithium Project and Tansim Lithium Project. The company also holds a 60% interest in the Moblan Lithium Project (Moblan). Its NAL comprises 19 contiguous claims covering over 582 hectares. Its Authier Lithium Project comprise of hard rock spodumene lithium deposit. Its Tansim Lithium Project is situated 82 kilometres south-west of the Authier project, which comprises 355 mineral claims. Its Moblan is located in the Eeyou-Istchee James Bay region of northern Quebec. The firm in Western Australia comprise lithium and gold tenure in the Pilbara and Yilgarn areas and graphite prospective tenements in the East Kimberley. Its projects include Deep Well Project, Tabba Tabba Project, Red Rock Project, Mallina Project (lithium), Mt Edon Lithium Project, Mt Dove Project, and Corkwood Graphite Project.